- Later today, AbbVie (ABBV -1.3%) will present more data from PEARL-1, the Phase 2b study of ABT-450/r — a collaborative effort with Enanta Pharmaceuticals (ENTA -0.2%) — in combination with ABT-267.
- 95% of GT-1b treatment-naïve patients and 90% of prior null responders achieved SVR12. (PR)
- More on recent developments in new HCV treatments here.
at Zacks.com (Nov 18, 2014)